Holmen Lab

Defining Critical Targets in Cancer Cells

Our lab is focused on defining critical targets in cancer cells that can become the focus for therapeutic intervention. Because of the high cost of developing new therapies, it is essential to first identify which genetic alterations can be productively targeted. We are concentrating our initial efforts on using a genetic approach in tumors that are refractory to conventional therapies including metastatic melanoma and glioblastoma. We plan to further validate these targets using pharmacological inhibitors of clinical importance.

News & Blog

4
Persistence Pays Off in Discovery That Could Lead to Improved Treatment and Survivability of Patients with Brain Tumors
clinical
May 01, 2018

Persistence Pays Off in Discovery That Could Lead to Improved Treatment and Survivability of Patients with Brain Tumors

Huntsman Cancer Institute,

Gliomas are the most common type of central nervous system cancer but how these tumors develop is not fully understood. Sheri Holmen, PhD a researcher at Huntsman Cancer Institute (HCI) and professor of surgery at the University of Utah just published the results of her research on gliomas in Cell Reports. The work is focused on a mutated gene that is a critical piece of the puzzle for glioma development, according to Holmen’s work.... Read More

sheri-holmen.jpg

Sheri L. Holmen, PhD
Principal Investigator
Sheri.Holmen@hci.utah.edu

Cancer Center Bio

Contact Us

Sheri Holmen
Huntsman Cancer Institute
2000 Circle of Hope, Rm 5263
Salt Lake City, UT 84112
Office: 801-213-4237